From this perspective, the ATM/CHK2/WEE1 pathway inhibitors cause the increased expression of PD-L1 in tumor cells and promote immune escape, so they are more suitable for the combined application of PD-1/PD-L1 inhibitors. The gene discussed is ATM; the disease is neoplasm.